TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer

Phase 2 Completed 52 enrolled Dutch Breast Cancer Research Group BOOG Study Center · collab Erasmus Medical Center · collab Servier · collab UMC Utrecht · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.

Timeline

Start: 2020-09-25
Primary completion: 2024-01-08
Completion: 2026-05-19

Outcome

Met primary endpoint

paper thereby meeting the primary endpoint of this study. PMID 40017682 ↗

Publications

Guchelaar NAD, Mathijssen RHJ, de Boer M, van Bekkum ML, Heijns JB, Vriens BEPJ, van Rosmalen MM, Kessels LW, Hamming L, Beelen KJ, Nieboer P, van den Berg SM, Hoop EO, Bijlsma RM, Bos MEMM; Dutch Breast Cancer Research Group (BOOG). Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial. EClinicalMedicine. 2025 Jan 27;80:103065. doi: 10.1016/j.eclinm.2024.103065. eCollection 2025 Feb.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	trifluridine-tipiracil	Unknown	35 mg/m2	Oral